Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.
Marmé F, Werft W, Walter A, Keller S, Wang X, Benner A, Burwinkel B, Sinn P, Hug S, Sohn C, Bretz N, Moldenhauer G, Rupp C, Rupp AK, Biakhov MY, Bottini A, Friedrichs K, Khailenko VA, Manikhas GM, Ruiz A, Sánchez-Rovira P, Santoro A, Segui MA, Villena C, Lichter P, Kristiansen G, Altevogt P, Schneeweiss A. Marmé F, et al. Breast Cancer Res Treat. 2012 Apr;132(3):819-31. doi: 10.1007/s10549-011-1759-9. Epub 2011 Sep 30. Breast Cancer Res Treat. 2012. PMID: 21960110 Clinical Trial.
Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.
Schneeweiss A, Lauschner I, Ruiz A, Guerrero A, Sánchez-Rovira P, Seguí MA, Goerke K, Wolf M, Manikhas AG, Wacker J, Marmé F, Lichter P, Sinn HP, Sohn C, Mansouri K, Bauknecht T, Hahn M. Schneeweiss A, et al. Among authors: marme f. Clin Breast Cancer. 2007 Apr;7(7):555-8. doi: 10.3816/CBC.2007.n.011. Clin Breast Cancer. 2007. PMID: 17509164 Clinical Trial.
Loss of Drop1 expression already at early tumor stages in a wide range of human carcinomas.
Marmé A, Zimmermann HP, Moldenhauer G, Schorpp-Kistner M, Müller C, Keberlein O, Giersch A, Kretschmer J, Seib B, Spiess E, Hunziker A, Merchán F, Möller P, Hahn U, Kurek R, Marmé F, Bastert G, Wallwiener D, Ponstingl H. Marmé A, et al. Among authors: marme f. Int J Cancer. 2008 Nov 1;123(9):2048-56. doi: 10.1002/ijc.23763. Int J Cancer. 2008. PMID: 18709643 Free article.
Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk.
Yang R, Dick M, Marme F, Schneeweiss A, Langheinz A, Hemminki K, Sutter C, Bugert P, Wappenschmidt B, Varon R, Schott S, Weber BH, Niederacher D, Arnold N, Meindl A, Bartram CR, Schmutzler RK, Müller H, Arndt V, Brenner H, Sohn C, Burwinkel B. Yang R, et al. Among authors: marme f. Breast Cancer Res Treat. 2011 Jun;127(2):549-54. doi: 10.1007/s10549-010-1244-x. Epub 2010 Nov 3. Breast Cancer Res Treat. 2011. PMID: 21046227
Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients.
Domschke C, Schuetz F, Ge Y, Rom J, Zorn M, Sinn HP, Marmé F, Schott S, Heil J, Scharf A, Sohn C, Schneeweiss A, Beckhove P. Domschke C, et al. Among authors: marme f. Cancer Immunol Immunother. 2011 Mar;60(3):401-11. doi: 10.1007/s00262-010-0956-4. Epub 2010 Dec 14. Cancer Immunol Immunother. 2011. PMID: 21161218 Free PMC article.
248 results